Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several safety and mechanism statements align with the provided label excerpts (infections risk, serious infection management, TB evaluation, hypersensitivity, and live vaccine avoidance). However, multiple claims are too general/unspecified or partially unsupported by the supplied label text, including several route/dosing-related assertions and infection-monitoring urgency/advice for older adults that are not explicitly stated in the provided label excerpts.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used to treat inflammatory conditions including psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Section 1 — INDICATIONS AND USAGE lists plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Cosentyx works by targeting interleukin-17A (IL-17A).
Provided label excerpt identifies secukinumab as an IL-17A antagonist.
Cosentyx may increase the risk of infections.
Section 5.1 — Infections: COSENTYX may increase risk of infections; higher infection rate vs placebo.
If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.
Section 5.1 — Infections: 'If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.'
Cosentyx may be less suitable if there is an active infection.
Section 5.1 — Infections advises exercise caution in chronic/recurrent infection; Section 5.3 — TB: 'Avoid administration of COSENTYX to patients with active TB infection.' The label excerpt supports withholding in active serious infections/TB context, though not universally for all active infections in the provided text.
Evaluate patients for active or latent TB infection prior to initiating treatment with COSENTYX.
Section 5.3 — Pre-Treatment Evaluation for Tuberculosis.
Avoid administration of COSENTYX to patients with active TB infection.
Section 5.3 — Pre-Treatment Evaluation for Tuberculosis.
Serious hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported.
Section 5.2 — Hypersensitivity Reactions.
Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations; Cosentyx may alter a patient's immune response to live vaccines; Avoid use of live vaccines in patients treated with Cosentyx.
Section 5.7 — Immunizations and Section 12.2 excerpt: 'Avoid use of live vaccines in patients treated with COSENTYX.'
Unsupported Statements
Dosing of biologic therapies is usually not adjusted based on kidney function in the same way as many small-molecule drugs.
The provided label excerpts do not discuss renal dosing considerations.
Dosing of biologic therapies is usually not adjusted based on liver function in the same way as many small-molecule drugs.
The provided label excerpts do not discuss hepatic dosing considerations.
The bigger question for biologics is how comorbid illnesses affect infection risk and overall tolerance rather than a direct kidney/liver dosing constraint.
Not stated in the provided label excerpts.
Before starting (and during treatment), clinicians typically assess whether the patient has any infection symptoms.
The label excerpts provided emphasize infection risk and close monitoring if serious infection occurs, but do not explicitly state routine assessment of infection symptoms 'before starting (and during treatment)'.
Before starting (and during treatment), clinicians typically assess past infection history.
The label excerpt says 'Exercise caution' in patients with chronic infection or history of recurrent infection, but does not explicitly describe a 'before starting (and during treatment)' assessment workflow.
Before starting (and during treatment), clinicians typically assess whether the patient is on other therapies that suppress immunity.
The provided label excerpts do not mention assessing concomitant immunosuppressive therapies in this specific manner.
Before starting (and during treatment), clinicians typically assess vaccination status because some vaccines may not be appropriate while on biologic therapy.
The label excerpt supports immunization planning prior to therapy and avoidance of live vaccines, but does not explicitly state routine 'during treatment' vaccination-status assessments.
If an elderly patient has multiple immune-related diagnoses or is taking other immunomodulators, clinicians may weigh risks more carefully.
The provided label excerpts do not provide this specific elderly/comorbidity/immunomodulator weighing statement.
Clinicians may weigh risks more carefully to reduce overlapping immune suppression while still controlling the underlying inflammatory disease.
The provided label excerpts support exercising caution and monitoring, but do not explicitly state this overlapping immune suppression rationale.
Older patients are advised to watch for signs of infection such as fever, worsening cough, burning with urination, or new/unusual symptoms.
No such explicit advice is included in the provided label excerpts.
Any infection concern is usually treated as urgent because older adults may worsen faster.
Not stated in the provided label excerpts.
Contradictions
Important Omissions
TB-specific monitoring details (e.g., 'during and after treatment') and latent TB treatment initiation prior to administering COSENTYX are not fully reflected in the response statements (only the general TB evaluation is covered).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Most infection-risk content is consistent with label excerpts; however, several statements provide general clinical guidance (older-adult urgency, symptom lists, routine 'before starting and during treatment' assessment workflows, and renal/hepatic dosing generalizations) that are not explicitly supported by the provided labeling, which could lead to overgeneralization.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts, especially those about routine pre-/during-treatment assessment workflow, older-adult symptom/urgency guidance, and renal/hepatic dosing generalizations.
Suggested Improvement
Restrict claims to what the supplied label text explicitly states: infections risk and management (monitoring/discontinue for serious infection), TB evaluation and avoidance in active TB, live vaccine avoidance and pre-initiation immunization planning, and avoid unsourced general statements about renal/hepatic dosing and older-adult urgency/symptom-check advice.